SDS
SE, AD
SHEEHAN, REMISSION
Results for the change in SDS total score numerically favored treatment with ESK + AD over AD + PBO. The mean (SD) change from baseline to Day 28 was -13.6 (8.31) for the ESK + AD group and -9.4 (8.43) for the AD + PBO group. Based on the MMRM model, the LS mean difference (95% CI) between the ESK + AD group and the AD + PBO group was -4.0 (-6.28, -1.64) (Fig. Change in the SDS score among patients included in the study using MMRM. AD + PBO, oral antidepressant plus placebo nasal spray; CI, confidence interval; ESK + AD, esketamine nasal spray plus oral antidepressant; LSM, least square mean; MMRM, mixed-effects model using repeated measures; SDS, Sheehan Disability Scale; SE, standard error. A responder analysis based on SDS total score at Day 28 found that 49 of 86 (57.0%) patients in the ESK + AD group and 34 of 86 (39.5%) patients in the AD + PBO group were responders, while 34 of 86 (39.5%) patients in the ESK + AD group and 18 of 86 (20.9%) patients in the AD + PBO group were in remission.